2Smolen JS,Landewe R,Breedveld FC,et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.Ann Rheum Dis,2010,69:964-975.
3Grigor C,Capell H,Stirling A,etal.Effect of a treatment st RA tegy of tight control for rheumatoid arthritis (the TICO RA study):a single-blind RA ndomised controlled trial.Lancet,2004,364:263-269.
4Goekoop-Ruiterman YP,de Vries-Bouwst RA JK,Allaart CF,et al.Patient preferences for treatment:report from a RA ndomised comparison of treatment st RA tegies in early rheumatoid arthritis (Best trial).Ann Rheum Dis,2007,66:1227-1232.
7Emery P.Evidence supporting the benefit of early intervention in rheumatoid arthritis.J Rheumatol.2002,66:Suppl.3-8.
8Peck JR,Smith TW.Ward JR,et al.Disability and depression in rheamatoid arthritis:a multi-trial.multi-method investigation.Arthritis Rheum.1989,32:1100-1106.
9ACR Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of RA. Arthritis Rheum, 2002, 46: 328- 346.
10Luqmani R, Hennell S, Estrach C, et al. British society for rheumatology and British health professionals in meumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology, 2006, 45:1167-1169.
5Yap DY,Tang CS,Ma MK. Survival analysis and causes of mortality in patients with lupus nephritis[J].{H}Nephrology Dialysis Transplantation,2012.3248-3254.
6Doria A,Iaccarino L,Ghirardello A. Long-term prognosis and causes of death in systemic lupus erythematosus[J].{H}American Journal of Medicine,2006.700-706.
7Zeevi A,Lunz J. Cylex ImmuKnow Cell Function Assay[J].{H}Methods in Molecular Biology,2013.343-351.
8Bombardier C,Gladman DD,Urowitz MB. Derivation of the SLEDAI.A disease activity index for lupus patients.The Committee on Prognosis Studies in SLE[J].{H}ARTHRITIS AND RHEUMATISM,1992.630-640.
9Kowalski R,Post D,Schneider MC. Immune cell function testing:an adjunct to therapeutic drug monitoring in transplant patient management[J].{H}Clinical Transplantation,2003.77-88.
10Szeto CC,Kwan BC,Lai FM. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis[J].{H}Rheumatology(Oxford),2008.1678-1681.
